tissueagnostic cancer drugs antineoplastic drugs treat cancers based mutations display instead tissue type tissueagnostic drugs approved medical use include pembrolizumab larotrectinib selpercatinib entrectinib pembrolizumab approved us food drug administration may larotrectinib approved fda november selpercatinib received priority review september approved medical use united states may entrectinib approved medical use united states august australia may european union july pralsetinib approved medical use united states september dabrafenib trametinib approved tissueagnostic drugs solid tumors braf positive tissueagnostic cancer drugs development may include selitrectinib antineoplastic immunomodulatory drug article stub help wikipedia expanding ithttpsenwikipediaorgwikitissueagnosticcancerdrug